Article says the Chinese State Food and Drug Adminstration (CFDA or SFDA) conducted an internal review of the drugs currently pending approval, and found out that in more than 80%:
the data failed to meet analysis requirements, were incomplete, or totally non-existent. [Also], many clinical trial outcomes were written before the trials had actually taken place. [...] The report found that pretty much everyone involved was guilty of some kind of malpractice of fraud. [...] even third party independent investigators tasked with inspecting clinical trial facilities are mentioned in the report as being “accomplices in data fabrication due to cut-throat competition and economic motivation”.
There’s no matching news item on the SFDA site; it probably doesn’t have an official version in English. The article linked relies on this and that.
Compare and contrast with Scott Alexander’s idea of making the American FDA regulate less. Two ends of a spectrum? Different cultures and markets leading to different outcomes? Similar situations but better hidden in the American case?
If the end result is fraud and bad medicine, whether you regulate more or less, is that a reason to regulate less so money isn’t wasted on mandatory fraudulent studies?
Regulation raises the the barrier of entry to selling medicine. Does this reduce the amount of fraud because it’s harder to to sell completely untested medicine and there’s at least some quality control by the regulator? Or does it increase the amount of fraud because once a drug costs huge amounts of money to develop and approve, companies are less willing to take a loss if they discover the drug doesn’t really work, and so lie more?
Let’s take New England Journal of Medicine. It’s a journal that pretends to do peer review. It’s the highest ranked journal in medicine.
The New England Journal of Medicine endorsed the CONSORT guidelines on best practice in trial reporting.
Does the peer review mean that authors who submit papers to the journal get told to modify their papers to fulfill the standards laid out in the CONSORT guidelines? No, the top rated journal in medicine doesn’t use peer review to make sure that the papers in their journal fulfill the standards that the journal endorsed.
What does the FDA do about such violations of scientific integrity? It doesn’t care. The NHI doesn’t even fund projects fighting it, so Ben Goldacre needed to get outside sources of money with the Laura and John Arnold Foundation (hedge fund billionaire money).
The problem with the FDA isn’t that they regulate a lot but that they regulate in the interests of Big Pharma instead of regulating in the interest of the citizens.
Tort reform also seems to be important in the US context and the example that Scott brought. It wasn’t just the FDA regulating but a company withdrawing their product to avoid getting sued.
If you don’t regulate truthfullness of published efficacy info, then companies will compete on advertising and bad studies to claim efficacy of their products. I don’t think that would lead to a marketplace where non-experts could reach correct conclusions about efficacy.
I have no real idea about the efficacy of most non-regulated things I’m sold, from deodorants and toothpaste to computer software. It’s just that with these things, the risk of occasionally buying something bad and learning not to use that anymore is acceptable. Not so with medicine.
Missing link: should point to Science Alert.
Article says the Chinese State Food and Drug Adminstration (CFDA or SFDA) conducted an internal review of the drugs currently pending approval, and found out that in more than 80%:
There’s no matching news item on the SFDA site; it probably doesn’t have an official version in English. The article linked relies on this and that.
Compare and contrast with Scott Alexander’s idea of making the American FDA regulate less. Two ends of a spectrum? Different cultures and markets leading to different outcomes? Similar situations but better hidden in the American case?
The FDA actually does regulate less than the CFDA in this case. The FDA doesn’t disapprove 80% of the drug seeking approval for misbehavior.
If you look at the Ranbaxy case the FDA is quite bad at detecting data forgery of generics companies.
This raises some interesting questions.
If the end result is fraud and bad medicine, whether you regulate more or less, is that a reason to regulate less so money isn’t wasted on mandatory fraudulent studies?
Regulation raises the the barrier of entry to selling medicine. Does this reduce the amount of fraud because it’s harder to to sell completely untested medicine and there’s at least some quality control by the regulator? Or does it increase the amount of fraud because once a drug costs huge amounts of money to develop and approve, companies are less willing to take a loss if they discover the drug doesn’t really work, and so lie more?
Let’s take New England Journal of Medicine. It’s a journal that pretends to do peer review. It’s the highest ranked journal in medicine. The New England Journal of Medicine endorsed the CONSORT guidelines on best practice in trial reporting.
Does the peer review mean that authors who submit papers to the journal get told to modify their papers to fulfill the standards laid out in the CONSORT guidelines? No, the top rated journal in medicine doesn’t use peer review to make sure that the papers in their journal fulfill the standards that the journal endorsed.
What does the FDA do about such violations of scientific integrity? It doesn’t care. The NHI doesn’t even fund projects fighting it, so Ben Goldacre needed to get outside sources of money with the Laura and John Arnold Foundation (hedge fund billionaire money).
The problem with the FDA isn’t that they regulate a lot but that they regulate in the interests of Big Pharma instead of regulating in the interest of the citizens.
Tort reform also seems to be important in the US context and the example that Scott brought. It wasn’t just the FDA regulating but a company withdrawing their product to avoid getting sued.
Don’t regulate efficiency. Regulate consistency of formulation, at most.
There are plenty of actors interested in efficacy. Really, everyone else involved.
What’s generally regulated is side-effects.
If you don’t regulate truthfullness of published efficacy info, then companies will compete on advertising and bad studies to claim efficacy of their products. I don’t think that would lead to a marketplace where non-experts could reach correct conclusions about efficacy.
I have no real idea about the efficacy of most non-regulated things I’m sold, from deodorants and toothpaste to computer software. It’s just that with these things, the risk of occasionally buying something bad and learning not to use that anymore is acceptable. Not so with medicine.